Turning Point Therapeutics Appoints Jim Mazzola to Lead Corporate Communication and Investor Relations

SAN DIEGO–(BUSINESS WIRE)–Turning Point Therapeutics, Inc., a clinical-stage precision oncology
company designing and developing novel drugs to address treatment
resistance, announced today the appointment of Jim Mazzola to lead
corporate communication and investor relations, reporting to Chief
Executive Officer Athena Countouriotis, M.D.

“Jim joins at a pivotal time for the company, and I am very excited to
work closely with him again,” said Dr. Countouriotis. “His background
complements the strong team we have been building to advance our
pipeline, make a difference in the lives of cancer patients and create
value for our investors.”

Mr. Mazzola brings nearly 30 years of public relations, financial
communication and marketing experience to the company, most recently
consulting for several biotechnology and medical-device companies. He
previously led communication and investor relations for Halozyme, and
before that served as senior vice president of global marketing,
communication and investor relations for CareFusion, responsible for the
company’s integrated marketing, communication and brand strategy,
investor relations, sales operations and serving as president of
the CareFusion Foundation. Prior to CareFusion, he was senior vice
president of global communication at Cardinal Health, where he led
corporate public relations, financial communication and the Cardinal
Health Foundation. Earlier in his career, he held communication and
marketing communication roles with technology companies Dell Computer
and NCR Corp. He earned his bachelor’s degree in communication and
M.B.A. from the University of Dayton.

About Turning Point Therapeutics, Inc.

Turning Point Therapeutics is a clinical-stage precision oncology
company with a pipeline of internally discovered investigational drugs
designed to address key limitations of existing cancer therapies. The
company’s lead program, repotrectinib, is a next-generation kinase
inhibitor targeting genetic drivers of non-small cell lung cancer and
advanced solid tumors. Repotrectinib has shown antitumor activity and
durable responses among kinase inhibitor treatment-naïve and pre-treated
patients, and is planned to enter a registrational Phase 2 study in the
second half of 2019. Turning Point’s kinase inhibitors are designed to
bind to their targets with greater precision and affinity than existing
therapies, with a novel, compact structure that has demonstrated an
ability to potentially overcome treatment resistance common with other
kinase inhibitors. The company is driven to develop therapies that mark
a turning point for patients in their cancer treatment. For more
information, visit www.tptherapeutics.com.

Contacts

Jim Mazzola
[email protected]
858-342-8272